National Psoriasis Foundation
Letter of Intent: December 13, 2019
Preventing the onset of disease, relapse or the related comorbidities would overcome many of the
obstacles that continue to challenge patients, health care providers and significantly improve the lives of those affected by psoriatic disease.
The National Psoriasis Foundation (NPF) has long recognized the importance of research to improve the lives of those living with psoriatic disease. The first pillar of our new five-year strategic plan is to lead collaborative, transformational research in psoriatic disease to support this mission. NPF is uniquely positioned to bring the research and the clinical community together to advance psoriatic disease research and support the use of successful strategies and models to address these challenges. To this end and inspired by the NIH Accelerating Medicines Partnership (AMP), NPF will invest an estimated $6.5 million over the next five years to establish the Psoriasis Prevention Initiative (PPI) – a multi-institution, multi-disciplinary, team-based research network whose stated aim is to identify an intervention that will prevent the onset of psoriatic disease, disease relapse or relevant comorbidities.
The NPF is seeking research proposals for this initiative based upon input from the PPI Steering
Committee, a group composed of members of the NPF’s Scientific Advisory Committee, NPF’s Medical Board, clinical advisors, bench and translational researchers, board members and patient constituents.
Proposals will be solicited from the international research community, with funding decisions based on a competitive, peer-review process. Highest priority will be given to proposals based on their ability to:
- Establish or develop innovative collaborations among basic, translational, and clinical
researchers.
- Identify a multi-faceted, multi-disciplinary, multi-institutional collaborative team and research approach.
- Explain how their approach will have the highest likelihood of developing an intervention that will:
- prevent the onset of psoriatic disease, or
- prevent the onset of psoriatic disease relapse, or
- prevent the onset of related comorbidities
Anticipated number of awards:
Up to two applications will be funded during the first year of the program. This award is contingent
upon the receipt of sufficiently meritorious applications for the first year, as well as for subsequent
renewal.
